BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Titov A, Zmievskaya E, Ganeeva I, Valiullina A, Petukhov A, Rakhmatullina A, Miftakhova R, Fainshtein M, Rizvanov A, Bulatov E. Adoptive Immunotherapy beyond CAR T-Cells. Cancers (Basel) 2021;13:743. [PMID: 33670139 DOI: 10.3390/cancers13040743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Kathuria-Prakash N, Drolen C, Hannigan CA, Drakaki A. Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches. Life (Basel) 2021;12:24. [PMID: 35054417 DOI: 10.3390/life12010024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Chasov V, Zaripov M, Mirgayazova R, Khadiullina R, Zmievskaya E, Ganeeva I, Valiullina A, Rizvanov A, Bulatov E. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. Front Immunol 2021;12:707734. [PMID: 34484205 DOI: 10.3389/fimmu.2021.707734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Fowler D, Nattress C, Navarrete AS, Barisa M, Fisher J. Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. Cancers (Basel) 2021;13:6000. [PMID: 34885108 DOI: 10.3390/cancers13236000] [Reference Citation Analysis]
4 Omata D, Munakata L, Maruyama K, Suzuki R. Ultrasound and microbubble-mediated drug delivery and immunotherapy. J Med Ultrasonics. [DOI: 10.1007/s10396-022-01201-x] [Reference Citation Analysis]
5 Zhang Y, He R, Lei X, Mao L, Jiang P, Ni C, Yin Z, Zhong X, Chen C, Zheng Q, Li D. A Novel Pyroptosis-Related Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Osteosarcoma. Front Genet 2021;12:780780. [PMID: 34899864 DOI: 10.3389/fgene.2021.780780] [Reference Citation Analysis]
6 Shah NN, Sokol L. Targeting CD22 for the Treatment of B-Cell Malignancies. Immunotargets Ther 2021;10:225-36. [PMID: 34262884 DOI: 10.2147/ITT.S288546] [Reference Citation Analysis]
7 Wang Y, Gu W, Wen W, Zhang X. SERPINH1 is a Potential Prognostic Biomarker and Correlated With Immune Infiltration: A Pan-Cancer Analysis. Front Genet 2021;12:756094. [PMID: 35058967 DOI: 10.3389/fgene.2021.756094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen J, Ding J, Huang W, Sun L, Chen J, Liu Y, Zhan Q, Gao G, He X, Qiu G, Long P, Wei L, Lu Z, Sun Y. DNASE1L3 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma Based on Data Mining. Front Genet 2021;12:699242. [PMID: 34868195 DOI: 10.3389/fgene.2021.699242] [Reference Citation Analysis]
9 Gotti E, Tettamanti S, Zaninelli S, Cuofano C, Cattaneo I, Rotiroti MC, Cribioli S, Alzani R, Rambaldi A, Introna M, Golay J. Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2021.11.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic. Crit Rev Biotechnol 2021;:1-20. [PMID: 34957875 DOI: 10.1080/07388551.2021.1988509] [Reference Citation Analysis]
11 Titov A, Kaminskiy Y, Ganeeva I, Zmievskaya E, Valiullina A, Rakhmatullina A, Petukhov A, Miftakhova R, Rizvanov A, Bulatov E. Knowns and Unknowns about CAR-T Cell Dysfunction. Cancers (Basel) 2022;14:1078. [PMID: 35205827 DOI: 10.3390/cancers14041078] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xie H, Xu J, Xie Z, Xie N, Lu J, Yu L, Li B, Cheng L. Identification and Validation of Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Necroptosis-Related Genes. Front Genet 2022;13:919638. [DOI: 10.3389/fgene.2022.919638] [Reference Citation Analysis]
13 Zhou L, Zou M, Xu Y, Lin P, Lei C, Xia X. Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics. Front Oncol 2022;12:864301. [PMID: 35664731 DOI: 10.3389/fonc.2022.864301] [Reference Citation Analysis]
14 Buitrago-Molina LE, Dywicki J, Noyan F, Schepergerdes L, Pietrek J, Lieber M, Schlue J, Manns MP, Wedemeyer H, Jaeckel E, Hardtke-Wolenski M. Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. Cells 2021;10:1471. [PMID: 34208308 DOI: 10.3390/cells10061471] [Reference Citation Analysis]
15 Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S, Cao Z, Sun S, Yu Z, Liu Y, Li N. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med 2021;19:140. [PMID: 34112147 DOI: 10.1186/s12916-021-02006-4] [Reference Citation Analysis]
16 Li X, Shao M, Zeng X, Qian P, Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther 2021;6:367. [PMID: 34667157 DOI: 10.1038/s41392-021-00764-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhang X, Liang H, Tang Q, Chen H, Guo F. Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer. Front Genet 2022;13:801665. [DOI: 10.3389/fgene.2022.801665] [Reference Citation Analysis]
18 Nydegger A, Novak U, Kronig MN, Legros M, Zeerleder S, Banz Y, Bacher U, Pabst T. Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. Cancers (Basel) 2021;13:6073. [PMID: 34885182 DOI: 10.3390/cancers13236073] [Reference Citation Analysis]
19 Sudarsanam H, Buhmann R, Henschler R. Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. Front Bioeng Biotechnol 2022;10:886637. [DOI: 10.3389/fbioe.2022.886637] [Reference Citation Analysis]
20 Dri DA, Gaucci E, Torrieri I, Carafa M, Marianecci C, Gramaglia D. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office. Pharmaceutics 2022;14:1438. [PMID: 35890333 DOI: 10.3390/pharmaceutics14071438] [Reference Citation Analysis]
21 Herrera L, Santos S, Vesga MA, Carrascosa T, Garcia-Ruiz JC, Pérez-Martínez A, Juan M, Eguizabal C. The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. Cancers (Basel) 2021;13:5418. [PMID: 34771581 DOI: 10.3390/cancers13215418] [Reference Citation Analysis]
22 Daly S, O'Sullivan A, MacLoughlin R. Cellular Immunotherapy and the Lung. Vaccines (Basel) 2021;9:1018. [PMID: 34579255 DOI: 10.3390/vaccines9091018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Suh MR, Lim I, Kim J, Yang PS, Choung JS, Sim HR, Ha SC, Kim M. Efficacy of Cord Blood Cell Therapy for Hutchinson-Gilford Progeria Syndrome-A Case Report. Int J Mol Sci 2021;22:12316. [PMID: 34830197 DOI: 10.3390/ijms222212316] [Reference Citation Analysis]